TY  - JOUR

T1  - Mepolizumab for treating severe eosinophilic asthma: an evidence review group perspective of a NICE single technology appraisal

JO  - Pharmacoeconomics

UR  - https://eprints.whiterose.ac.uk/id/eprint/121723

PY  - 2017/09/20

AU  - Bermejo I

AU  - Stevenson M

AU  - Cooper K

AU  - Harnan S

AU  - Hamilton J

AU  - Clowes M

AU  - Carroll C

AU  - Harrison T

AU  - Saha S

ED  - 

DO  - DOI: 10.1007/s40273-017-0571-8

PB  - Adis

VL  - 36

SP  - 131

EP  - 144

Y2  - 2025/10/31

ER  -